Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis.
Adult
D-Aspartic Acid
/ administration & dosage
Evoked Potentials, Motor
/ drug effects
Female
Humans
Long-Term Potentiation
/ drug effects
Male
Middle Aged
Multiple Sclerosis, Chronic Progressive
/ drug therapy
Neuronal Plasticity
/ drug effects
Receptors, N-Methyl-D-Aspartate
/ drug effects
Transcranial Magnetic Stimulation
D-Aspartate
disability
long-term potentiation
synaptic plasticity
theta burst stimulation
transcranial magnetic stimulation
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
8
2
2019
medline:
16
3
2021
entrez:
8
2
2019
Statut:
ppublish
Résumé
Synaptic plasticity reserve correlates with clinical recovery after a relapse in relapsing-remitting forms of multiple sclerosis (MS) and is significantly compromised in patients with progressive forms of MS. These findings suggest that progression of disability in MS is linked to reduced synaptic plasticity reserve. D-Aspartate, an endogenous aminoacid approved for the use in humans as a dietary supplement, enhances synaptic plasticity in mice. To test whether D-Aspartate oral intake increases synaptic plasticity reserve in progressive MS patients. A total of 31 patients affected by a progressive form of MS received either single oral daily doses of D-Aspartate 2660 mg or placebo for 4 weeks. Synaptic plasticity reserve and trans-synaptic cortical excitability were measured through transcranial magnetic stimulation (TMS) protocols before and after D-Aspartate. Both TMS-induced long-term potentiation (LTP), intracortical facilitation (ICF) and short-interval ICF increased after 2 and 4 weeks of D-Aspartate but not after placebo, suggesting an enhancement of synaptic plasticity reserve and increased trans-synaptic glutamatergic transmission. Daily oral D-Aspartate 2660 mg for 4 weeks enhances synaptic plasticity reserve in patients with progressive MS, opening the path to further studies assessing its clinical effects on disability progression.
Sections du résumé
BACKGROUND
Synaptic plasticity reserve correlates with clinical recovery after a relapse in relapsing-remitting forms of multiple sclerosis (MS) and is significantly compromised in patients with progressive forms of MS. These findings suggest that progression of disability in MS is linked to reduced synaptic plasticity reserve. D-Aspartate, an endogenous aminoacid approved for the use in humans as a dietary supplement, enhances synaptic plasticity in mice.
OBJECTIVE
To test whether D-Aspartate oral intake increases synaptic plasticity reserve in progressive MS patients.
METHODS
A total of 31 patients affected by a progressive form of MS received either single oral daily doses of D-Aspartate 2660 mg or placebo for 4 weeks. Synaptic plasticity reserve and trans-synaptic cortical excitability were measured through transcranial magnetic stimulation (TMS) protocols before and after D-Aspartate.
RESULTS
Both TMS-induced long-term potentiation (LTP), intracortical facilitation (ICF) and short-interval ICF increased after 2 and 4 weeks of D-Aspartate but not after placebo, suggesting an enhancement of synaptic plasticity reserve and increased trans-synaptic glutamatergic transmission.
CONCLUSION
Daily oral D-Aspartate 2660 mg for 4 weeks enhances synaptic plasticity reserve in patients with progressive MS, opening the path to further studies assessing its clinical effects on disability progression.
Identifiants
pubmed: 30730244
doi: 10.1177/1352458519828294
doi:
Substances chimiques
Receptors, N-Methyl-D-Aspartate
0
D-Aspartic Acid
4SR0Q8YD1X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM